Condition
Autism Spectrum Disorder With Impaired Functional Language
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Unknown1
Active Not Recruiting1
Completed1
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06064422Not ApplicableCompleted
Adapting BA for Minimally Verbal Autistic Adults
NCT07521371Enrolling By Invitation
Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years
NCT05663970Not ApplicableActive Not Recruiting
Virtual Group Social ABCs - Multi-site Randomized Controlled Trial
NCT05511220Not ApplicableUnknownPrimary
Pivotal Response Intervention Minimal Responders Study
Showing all 4 trials